Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
A phase 2 trial of Vorolanib in Renal cell carcinoma, run by Dong Wen, active and no longer recruiting.
Overview
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07047001 by Dong Wen, with 60 participants planned, started 2025-04-24 and due to reach its primary completion in 2029-06-30. Interventions recorded: Vorolanib Tablets, Vorolanib + Toripalimab. Conditions recorded: Renal Cell Carcinoma (RCC), Adjuvant.
Linked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialVorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Shares Vorolanib, Renal cell carcinoma and the tag pipeline.
- TrialVorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Shares Vorolanib and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Renal cell carcinoma and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialStudy of ST-1898 in Advanced Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Renal cell carcinoma and the tag pipeline.
- TrialAn Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Shares Renal cell carcinoma and the tag pipeline.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares Renal cell carcinoma and the tag pipeline.